Edward M Schaeffer

List of Publications by Year
in descending order

191 papers	8,326 citations	53660 45 h-index	53109 85 g-index
193 all docs	193 docs citations	193 times ranked	10271 citing authors

#	Article	IF	Citations
1	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	2.3	943
2	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	2.3	544
3	Complications After Systematic, Random, and Image-guided Prostate Biopsy. European Urology, 2017, 71, 353-365.	0.9	353
4	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	2.3	299
5	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	2.3	294
6	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	3.4	288
7	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	3.4	219
8	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nature Reviews Urology, 2017, 14, 15-25.	1.9	210
9	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 157-165.	0.9	206
10	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncology, The, 2016, 17, 1612-1620.	5.1	182
11	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology, 2017, 35, 1991-1998.	0.8	176
12	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
13	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Research, 2016, 76, 4948-4958.	0.4	147
14	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal of the National Cancer Institute, 2019, 111, 301-310.	3.0	142
15	Pathological Examination of Radical Prostatectomy Specimens in Men with Very Low Risk Disease at Biopsy Reveals Distinct Zonal Distribution of Cancer in Black American Men. Journal of Urology, 2014, 191, 60-67.	0.2	127
16	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 2789-2796.	0.8	127
17	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology, 2015, 68, 555-567.	0.9	125
18	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nature Communications, 2019, 10, 4358.	5.8	109

#	Article	IF	Citations
19	TWIST1-WDR5-*Hottip* Regulates *Hoxa9* Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Research, 2017, 77, 3181-3193.	0.4	102
20	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	2.9	99
21	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European Urology, 2021, 79, 374-383.	0.9	93
22	The evolving genomic landscape of urothelial carcinoma. Nature Reviews Urology, 2017, 14, 215-229.	1.9	89
23	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clinical Cancer Research, 2017, 23, 7072-7083.	3.2	87
24	Racial Differences in Genomic Profiling of Prostate Cancer. New England Journal of Medicine, 2020, 383, 1083-1085.	13.9	87
25	Prostate Specific Membrane Antigen Targeted [18] F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. Journal of Urology, 2018, 199, 126-132.	0.2	86
26	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. European Urology, 2016, 70, 14-17.	0.9	79
27	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncology, The, 2021, 22, 402-410.	5.1	79
28	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. Journal of Clinical Oncology, 2017, 35, 1982-1990.	0.8	76
29	The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. European Urology, 2017, 71, 174-180.	0.9	75
30	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a *de novo* low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clinical Cancer Research, 2019, 25, 6721-6730.	3.2	74
31	Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer. European Urology, 2018, 74, 146-154.	0.9	72
32	Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Modern Pathology, 2018, 31, 1539-1552.	2.9	70
33	Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. European Urology, 2017, 71, 697-700.	0.9	65
34	Reclassification Rates Are Higher Among African American Men Than Caucasians on Active Surveillance. Urology, 2015, 85, 155-160.	0.5	64
35	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clinical Cancer Research, 2020, 26, 3182-3192.	3.2	64
36	Prostate Specific Antigen Testing Among the Elderly—When To Stop?. Journal of Urology, 2009, 181, 1606-1614.	0.2	63

#	Article	IF	Citations
37	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of *TP53* Missense Mutation in Prostate Cancer. Clinical Cancer Research, 2017, 23, 4693-4703.	3.2	62
38	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Modern Pathology, 2021, 34, 1185-1193.	2.9	61
39	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology, 2018, 73, 524-532.	0.9	60
40	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncology, 2020, 6, 735.	3.4	58
41	Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up. Urology, 2014, 84, 1434-1441.	0.5	56
42	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research, 2015, 21, 5619-5629.	3.2	56
43	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nature Communications, 2021, 12, 935.	5.8	56
44	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nature Communications, 2022, 13, 2559.	5.8	56
45	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. European Urology, 2018, 74, 107-114.	0.9	54
46	A PRC2-independent function for EZH2 in regulating rRNA 2â€²-O methylation and IRES-dependent translation. Nature Cell Biology, 2021, 23, 341-354.	4.6	54
47	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. European Urology, 2018, 73, 168-175.	0.9	53
48	Magnetic Resonanceâ€"invisible Versus Magnetic Resonanceâ€"visible Prostate Cancer in Active Surveillance: AÂ Preliminary Report on Disease Outcomes. Urology, 2015, 85, 147-154.	0.5	50
49	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Communications Biology, 2021, 4, 670.	2.0	50
50	Inflammatory Bowel Disease and the Risk of Prostate Cancer. European Urology, 2019, 75, 846-852.	0.9	47
51	Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomeraseâ€"inhibiting therapy. BJU International, 2010, 106, 62-65.	1.3	46
52	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clinical Cancer Research, 2016, 22, 1777-1786.	3.2	42
53	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. European Urology, 2016, 69, 576-581.	0.9	42
54	Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 309-320.	1.8	42

#	Article	IF	Citations
55	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. Journal of Urology, 2016, 196, 1436-1444.	0.2	38
56	Outcomes of very high‐risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer, 2019, 125, 391-397.	2.0	37
57	Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database. Journal of Urology, 2017, 197, 627-631.	0.2	35
58	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. Human Pathology, 2019, 87, 95-102.	1.1	34
59	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. Journal of Urology, 2017, 197, 122-128.	0.2	33
60	Gender Representation in Urologic Subspecialties. Urology, 2018, 114, 66-70.	0.5	32
61	The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004–2013). Urologic Oncology: Seminars and Original Investigations, 2018, 36, 91.e1-91.e6.	0.8	32
62	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	0.9	32
63	Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. Journal of Urology, 2018, 199, 1510-1517.	0.2	31
64	Fluoroquinolone Resistance in the Rectal Carriage of Men in an Active Surveillance Cohort: Longitudinal Analysis. Journal of Urology, 2015, 193, 552-556.	0.2	29
65	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget, 2017, 8, 50804-50813.	0.8	29
66	Association between inflammatory bowel disease and prostate cancer: A large‐scale, prospective, population‐based study. International Journal of Cancer, 2020, 147, 2735-2742.	2.3	28
67	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	1.8	26
68	Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. European Urology Open Science, 2022, 37, 53-63.	0.2	26
69	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clinical Cancer Research, 2018, 24, 3908-3916.	3.2	24
70	Cause of death during prostate cancer survivorship: A contemporary, US population–based analysis. Cancer, 2021, 127, 2895-2904.	2.0	24
71	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 496-504.	0.9	23
72	Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 2020, 80, 1012-1023.	1.2	22

#	Article	IF	Citations
73	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	1.2	21
74	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. Oncotarget, 2017, 8, 104182-104192.	0.8	20
75	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. European Urology Oncology, 2019, 2, 589-596.	2.6	19
76	African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. Journal of Urology, 2019, 202, 247-255.	0.2	19
77	Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. Journal of Urology, 2020, 203, 933-939.	0.2	19
78	HES6 promotes prostate cancer aggressiveness independently of Notch signalling. Journal of Cellular and Molecular Medicine, 2015, 19, 1624-1636.	1.6	18
79	Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. Urology, 2016, 90, 136-140.	0.5	18
80	Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. International Journal of Cancer, 2019, 145, 3453-3461.	2.3	18
81	The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods. Urology, 2019, 129, 153-159.	0.5	18
82	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology, 2020, 78, 327-332.	0.9	18
83	Duplex ultrasonography detects clinically significant anomalies of penile arterial vasculature affecting surgical approach to penile straightening. Urology, 2006, 67, 166-169.	0.5	17
84	Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)â€"Induced Cancer at Multiple Sites. Cancer Prevention Research, 2015, 8, 683-692.	0.7	17
85	Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer. Bladder Cancer, 2017, 3, 45-49.	0.2	17
86	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clinical Cancer Research, 2019, 25, 5608-5622.	3.2	17
87	Prostate cancer in sexual minorities and the influence of HIV status. Nature Reviews Urology, 2019, 16, 404-421.	1.9	17
88	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer and Prostatic Diseases, 2020, 23, 646-653.	2.0	17
89	Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy. Journal of Urology, 2017, 197, 1245-1250.	0.2	16
90	Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. Journal of Molecular Diagnostics, 2017, 19, 475-484.	1.2	16

#	Article	IF	Citations
91	A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort. BMC Urology, 2019, 19, 121.	0.6	16
92	*CDKN1B* Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. Clinical Cancer Research, 2020, 26, 2595-2602.	3.2	16
93	Association of B7â€H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer, 2022, 128, 2269-2280.	2.0	16
94	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. JAMA Network Open, 2021, 4, e2139769.	2.8	16
95	The History of Prostate Cancer From Antiquity: Review of Paleopathological Studies. Urology, 2016, 97, 8-12.	0.5	15
96	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	14
97	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. European Urology Oncology, 2019, 2, 405-412.	2.6	14
98	Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. European Urology Oncology, 2021, 4, 955-962.	2.6	14
99	SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy. Prostate Cancer and Prostatic Diseases, 2019, 22, 552-559.	2.0	13
100	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. European Urology, 2021, 79, 717-721.	0.9	13
101	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. PLoS ONE, 2016, 11, e0146189.	1.1	13
102	Grade Migration of Prostate Cancer in the United States During the Last Decade. Journal of the National Cancer Institute, 2022, 114, 1012-1019.	3.0	13
103	Inguinal bladder hernia. Urology, 2003, 62, 940.	0.5	12
104	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer and Prostatic Diseases, 2020, 23, 179-183.	2.0	12
105	Neoadjuvant randomized trial of degarelix (Deg) Â± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. Journal of Clinical Oncology, 2017, 35, 5077-5077.	0.8	12
106	Prophylactic use of antimicrobials in commonly performed outpatient urologic procedures. Nature Reviews Urology, 2006, 3, 24-31.	1.4	11
107	The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 Years. Urology Practice, 2020, 7, 145-151.	0.2	11
108	Risk Factors for Infection after Prostate Biopsy in the United States. Urology, 2020, 138, 113-118.	0.5	11

#	Article	IF	Citations
109	A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host. Oncotarget, 2019, 10, 6845-6854.	0.8	11
110	Reporting of Racial Health Disparities Research: Are We Making Progress?. Journal of Clinical Oncology, 2022, 40, 8-11.	0.8	11
111	Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified?. Urology, 2015, 86, 942-946.	0.5	10
112	Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 292-302.	2.0	10
113	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. JAMA Oncology, 2020, 6, 1793.	3.4	10
114	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. Journal of Clinical Medicine, 2020, 9, 1973.	1.0	10
115	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1376-1383.	1.1	9
116	Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	9
117	Changes in prostate–specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men. Cancer, 2020, 126, 3229-3236.	2.0	9
118	A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 659-665.	2.0	9
119	AMYLOIDOSIS OF THE SEMINAL VESICLE AND HEMATOSPERMIA. Journal of Urology, 2004, 171, 2382-2382.	0.2	8
120	Real-world use of MRI for risk stratification prior to prostate biopsy. Prostate Cancer and Prostatic Diseases, 2023, 26, 353-359.	2.0	8
121	ADRENAL MYELOLIPOMA. Journal of Urology, 2005, 173, 1760-1760.	0.2	7
122	Definitive and sustained increase in prostate cancer metastases in the United States. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 988-990.	0.8	7
123	Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. European Urology, 2022, 81, 325-330.	0.9	7
124	A novel immunocompetent model of metastatic prostate cancer–induced bone pain. Prostate, 2020, 80, 782-794.	1.2	6
125	Performance of prostate health index and PSA density in a diverse biopsy–naïve cohort with mpMRI for detecting significant prostate cancer. BJUI Compass, 2021, 2, 370-376.	0.7	6
126	Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines. Urology, 2020, 135, 1-3.	0.5	5

#	Article	IF	Citations
127	Local anaesthetic techniques for performing transperineal prostate biopsy. Nature Reviews Urology, 2021, 18, 315-317.	1.9	5
128	It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?. Cancer, 2021, 127, 3354-3360.	2.0	5
129	Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.. Journal of Clinical Oncology, 2020, 38, 24-24.	0.8	5
130	Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk.. Journal of Clinical Oncology, 2017, 35, 5000-5000.	0.8	4
131	Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer. Urology Case Reports, 2016, 7, 64-66.	0.1	2
132	Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer, 2017, 123, 2240-2247.	2.0	2
133	The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study. Journal of Urology, 2018, 200, 1048-1055.	0.2	2
134	National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 353.e1-353.e8.	0.8	2
135	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	1.5	2
136	Association between surgical approach and survival following resection of abdominopelvic malignancies. Journal of Surgical Oncology, 2020, 121, 620-629.	0.8	2
137	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.2	2
138	Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort.. Journal of Clinical Oncology, 2015, 33, 5059-5059.	0.8	2
139	Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility.. Journal of Clinical Oncology, 2016, 34, 303-303.	0.8	2
140	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5020-5020.	0.8	2
141	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 35, 3-3.	0.8	2
142	Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues.. Journal of Clinical Oncology, 2017, 35, 38-38.	0.8	2
143	High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. Prostate Cancer and Prostatic Diseases, 2023, 26, 105-112.	2.0	2
144	Iatrogenic Extraprostatic Extension of Prostate Cancer From a Needle Biopsy. Urology Case Reports, 2015, 3, 56-58.	0.1	1

#	Article	IF	Citations
145	Re: Steven Joniau, Alberto Briganti, Paolo Gontero, et al. Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. Eur Urol 2015;67:157â€"64. European Urology, 2015, 68, e11-e12.	0.9	1
146	Progress in Prognosis and Prediction for Men with Prostate Cancer. European Urology, 2017, 72, 32-33.	0.9	1
147	Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk. European Urology, 2018, 74, 453-454.	0.9	1
148	TNF-alpha immunosuppressive use and future malignancy risk.. Journal of Clinical Oncology, 2021, 39, 10558-10558.	0.8	1
149	Development and validation of genomic signature to predict ADT treatment failure.. Journal of Clinical Oncology, 2016, 34, 5018-5018.	0.8	1
150	Race, demographics, and socioeconomics as they relate to newly diagnosed metastatic prostate cancer in the United States.. Journal of Clinical Oncology, 2017, 35, 195-195.	0.8	1
151	Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 5033-5033.	0.8	1
152	Recalibrationâ€¦ofâ€¦genomicâ€¦riskâ€¦predictionâ€¦modelsâ€¦inâ€¦prostateâ€¦cancerâ€¦toâ€¦improveâ€¦individual-levelâ€¦ Journal of Clinical Oncology, 2015, 33, e16122-e16122.	0.8	1
153	The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.. Journal of Clinical Oncology, 2016, 34, 256-256.	0.8	1
154	Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.. Journal of Clinical Oncology, 2017, 35, 133-133.	0.8	1
155	Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.. Journal of Clinical Oncology, 2018, 36, 2-2.	0.8	1
156	Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests.. Journal of Clinical Oncology, 2020, 38, 348-348.	0.8	1
157	Cystoscopic Management of an Extruded Coil from Arteriovenous Fistula Embolization Using Arthroscopic Instruments. Journal of Endourology, 2008, 22, 1527-1530.	1.1	0
158	Editorial Comment. Urology, 2014, 84, 1261-1262.	0.5	0
159	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. Urology Case Reports, 2016, 6, 45-46.	0.1	0
160	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports, 2016, 9, 51-54.	0.1	0
161	â€œReal-worldâ€•Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. European Urology, 2018, 74, 708-709.	0.9	0
162	Abstract 2546: Predictive value of prostate health index (PHI) in multi-parametric MRI in an ethnically diverse cohort. , 2021, , .		0

#	Article	IF	Citations
163	Influence of Department Leadership on Scholarly Productivity and Research Funding in Academic Urology. Urology, 2021, 154, 136-140.	0.5	0
164	Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 52-52.	0.8	0
165	The role of advanced genetic testing in the management of prostate cancer post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 5089-5089.	0.8	0
166	Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification.. Journal of Clinical Oncology, 2014, 32, 91-91.	0.8	0
167	An expression-guided screen for small molecules targeting aggressive prostate cancer.. Journal of Clinical Oncology, 2014, 32, e16081-e16081.	0.8	0
168	The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy.. Journal of Clinical Oncology, 2014, 32, 5036-5036.	0.8	0
169	Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.. Journal of Clinical Oncology, 2016, 34, 106-106.	0.8	0
170	Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.. Journal of Clinical Oncology, 2016, 34, 12-12.	0.8	0
171	Effect of local therapy on the systemic anti-tumor response in prostate cancer.. Journal of Clinical Oncology, 2016, 34, 243-243.	0.8	0
172	Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 299-299.	0.8	0
173	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	0.8	0
174	Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility in radical prostatectomy tissues.. Journal of Clinical Oncology, 2016, 34, 5055-5055.	0.8	0
175	Validation of a genomic risk classifier to predict prostate cancer-specific mortality (PCSM) in high-risk patients.. Journal of Clinical Oncology, 2016, 34, 5056-5056.	0.8	0
176	The impact of race on perceptions of anxiety after radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, e538-e538.	0.8	0
177	Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model.. Journal of Clinical Oncology, 2017, 35, 142-142.	0.8	0
178	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 2017, 3-3.	0.8	0
179	Temporal trends and factors associated with overuse of neoadjuvant androgen deprivation therapy in low and very low risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 28-28.	0.8	0
180	The influence of decision aids on prostate cancer screening preferences: A randomized survey study.. Journal of Clinical Oncology, 2018, 36, 5085-5085.	0.8	0

#	Article	IF	Citations
181	Inflammatory bowel disease and the risk of prostate cancer.. Journal of Clinical Oncology, 2018, 36, e17052-e17052.	0.8	0
182	Risk factors for postprostate biopsy infection.. Journal of Clinical Oncology, 2019, 37, 103-103.	0.8	0
183	Percent genome alteration and outcomes after radical prostatectomy in African American men.. Journal of Clinical Oncology, 2019, 37, 24-24.	0.8	0
184	SPINK1 expression and outcomes postprostatectomy in race-specific cohorts.. Journal of Clinical Oncology, 2019, 37, 23-23.	0.8	0
185	Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.. Journal of Clinical Oncology, 2019, 37, 55-55.	0.8	0
186	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. Journal of Clinical Oncology, 2019, 37, TPS333-TPS333.	0.8	0
187	National society-supplied patient materials on prostate cancer screening for the general public: A readability analysis.. Journal of Clinical Oncology, 2019, 37, e23188-e23188.	0.8	0
188	Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.. Journal of Clinical Oncology, 2020, 38, 337-337.	0.8	0
189	Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer.. Journal of Clinical Oncology, 2020, 38, 295-295.	0.8	0
190	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. Journal of Clinical Oncology, 2020, 38, e17517-e17517.	0.8	0
191	Abstract 462: Using attention-based deep multiple instance learning to identify key genetic alterations in prostate cancer from whole slide images. Cancer Research, 2022, 82, 462-462.	0.4	0